1. A 28-year-old woman presents with a 3-month history of palpitations, weight loss despite increased appetite, heat intolerance, and a diffuse goiter. TSH is suppressed and free T4 is elevated. Thyroid-stimulating immunoglobulin (TSI) is markedly positive. Which of the following best explains why her hyperthyroid state persists despite markedly suppressed TSH?
A) Follicular cell somatic mutations constitutively activate adenylyl cyclase independent of receptor binding
B) TSIs bind and chronically activate the TSH receptor, driving cAMP-mediated hormone synthesis without pituitary feedback suppression
C) Excess iodide from dietary sources overwhelms the Wolff-Chaikoff inhibitory mechanism
E) TSH receptor downregulation in the pituitary prevents normal negative feedback by thyroid hormone
ANSWER: B
Rationale:
Option B is correct. Thyroid-stimulating immunoglobulins (TSIs) are IgG autoantibodies that bind the TSH (thyroid-stimulating hormone) receptor on follicular cells and activate the same Gs-protein/cyclic adenosine monophosphate (cAMP) signaling cascade as TSH itself. Unlike TSH, which is subject to negative feedback suppression when circulating thyroid hormone rises, TSIs are immunoglobulins produced by B cells and are not regulated by thyroid hormone levels. The result is autonomous, continuous receptor activation that drives unregulated thyroid hormone synthesis and secretion — precisely the mechanism that sustains Graves' disease even as TSH falls to undetectable levels. This explains the hallmark laboratory pattern: suppressed TSH with elevated free T4 and T3.
Option A: Option A describes the mechanism of toxic multinodular goiter (TMNG) or toxic adenoma, in which somatic mutations in the TSH receptor or Gsα subunit constitutively activate adenylyl cyclase without TSI involvement; TRAb are negative in these conditions.
Option C: Option C is incorrect; the Wolff-Chaikoff effect represents transient inhibition of organification by excess iodide, not a mechanism of disease in Graves' disease.
Option D: Option D is incorrect; TPO is inhibited, not degraded, by thionamide drugs, and autoantibodies do not act via TPO degradation blockade.
Option E: Option E is incorrect; TSH receptor downregulation in the pituitary is not the mechanism; TSH suppression in Graves' disease results from the standard negative feedback loop — high circulating thyroid hormone suppresses pituitary TSH secretion normally, but TSI-driven follicular stimulation continues regardless.
2. A patient with Graves' disease is started on methimazole. The pharmacist explains that methimazole will take 2–4 weeks before significant clinical improvement occurs. Which of the following correctly identifies the primary biochemical mechanism of methimazole and the reason for this therapeutic delay?
A) Methimazole blocks the sodium-iodide symporter (NIS), preventing iodide uptake; the delay reflects slow NIS downregulation
B) Methimazole inhibits type 1 deiodinase in peripheral tissues; the delay reflects accumulation of the inactive drug metabolite
C) Methimazole blocks TSH receptor binding; the delay reflects the time required to clear circulating TSIs
D) Methimazole inhibits thyroid peroxidase (TPO), blocking iodide organification and iodotyrosine coupling; the delay reflects depletion of preformed hormone stored as thyroglobulin in follicular colloid
E) Methimazole suppresses pituitary TSH secretion; the delay reflects the time required for TSH-driven follicular hypertrophy to resolve
ANSWER: D
Rationale:
Option D is correct. Methimazole exerts its antithyroid effect by inhibiting thyroid peroxidase (TPO), the enzyme responsible for two sequential reactions within the follicular lumen: (1) oxidative organification of iodide to reactive iodine species, and (2) coupling of iodotyrosine residues (monoiodotyrosine and diiodotyrosine) on thyroglobulin to form T3 and T4. By blocking both reactions, methimazole halts new thyroid hormone synthesis. The 2–4 week delay before clinical improvement reflects the fact that methimazole does not block release of preformed thyroid hormone already stored as iodinated thyroglobulin in the follicular colloid; the thyroid gland normally maintains a 2–3 month hormonal reserve. Clinical improvement requires ongoing secretion to deplete this colloid store while new synthesis is blocked.
Option A: Option A is incorrect; the sodium-iodide symporter (NIS) is not the target of thionamides. NIS inhibition occurs with competitive anions such as perchlorate and thiocyanate.
Option B: Option B is incorrect; peripheral type 1 deiodinase (D1) inhibition is a property of PTU, not methimazole; furthermore, the therapeutic delay relates to colloid stores, not drug metabolite accumulation.
Option C: Option C is incorrect; methimazole does not bind TSH receptors or block TSI activity; it acts at the enzymatic level within the follicle.
Option E: Option E is incorrect; methimazole does not suppress TSH directly; as methimazole lowers thyroid hormone levels, TSH rises (negative feedback normalization), and follicular hypertrophy is not the mechanism of the therapeutic lag.
3. A patient in thyroid storm is being initiated on propylthiouracil (PTU) rather than methimazole. Beyond their shared ability to inhibit thyroid peroxidase (TPO), which additional pharmacodynamic property of PTU makes it the preferred thionamide in this acute setting?
A) PTU inhibits type 1 deiodinase (D1) in peripheral tissues, reducing conversion of thyroxine (T4) to the more potent triiodothyronine (T3) by approximately 40%
B) PTU inhibits thyroid hormone secretion by blocking thyroglobulin proteolysis, reducing the release of preformed hormone from follicular colloid
C) PTU activates hepatic glucuronidation of T4, accelerating systemic clearance of circulating thyroid hormone
D) PTU competitively blocks T3 binding at nuclear thyroid hormone receptors, reducing genomic effects at target tissues
E) PTU inhibits the sodium-iodide symporter (NIS) at high doses, reducing iodide uptake by follicular cells
ANSWER: A
Rationale:
Option A is correct. PTU shares TPO inhibition with methimazole but uniquely inhibits type 1 deiodinase (D1), the enzyme responsible for the majority of extrathyroidal conversion of thyroxine (T4) to triiodothyronine (T3). T3 is approximately 3–4 times more potent than T4 at nuclear thyroid hormone receptors, so reducing peripheral T3 generation has immediate therapeutic relevance in thyroid storm where T3-mediated adrenergic hyperactivation is driving multi-organ decompensation. PTU's D1 inhibition reduces circulating T3 by approximately 40% and produces a faster fall in serum T3 compared with methimazole, even though overall thyroid hormone normalization is slower with PTU. This dual mechanism — TPO inhibition plus D1 blockade — is the pharmacological basis for selecting PTU over methimazole in thyroid storm.
Option B: Option B is incorrect; neither thionamide blocks thyroglobulin proteolysis or inhibits preformed hormone release; iodide and glucocorticoids partially inhibit secretion of preformed hormone, but thionamides act only at the synthesis level.
Option C: Option C is incorrect; PTU does not activate hepatic glucuronidation pathways; no thionamide accelerates thyroid hormone clearance through hepatic conjugation.
Option D: Option D is incorrect; PTU does not act at the nuclear receptor level; its actions are entirely presynaptic to receptor binding, at the level of synthesis and peripheral conversion.
Option E: Option E is incorrect; NIS inhibition is the mechanism of perchlorate and thiocyanate, not thionamides; thionamides act downstream of iodide uptake.
4. A resident asks why patients with newly diagnosed Graves' disease do not feel better within a few days of starting methimazole even when the dose is adequate. Which of the following is the most accurate explanation for the 2–4 week lag before significant clinical improvement?
A) Methimazole requires hepatic activation to its active metabolite, and this biotransformation is rate-limiting
B) Thyroid-stimulating immunoglobulins (TSIs) continue to stimulate the TSH receptor for weeks after methimazole is started, overriding the drug's TPO inhibition
C) Methimazole blocks new thyroid hormone synthesis but does not release preformed T4 and T3 stored as iodinated thyroglobulin in follicular colloid; clinical improvement requires depletion of this reserve through ongoing secretion
D) Methimazole is highly protein-bound and requires weeks to achieve steady-state tissue concentrations within the thyroid gland
E) The pituitary requires 2–4 weeks after starting methimazole to normalize TSH secretion, and TSH normalization is necessary before thyroid hormone levels fall
ANSWER: C
Rationale:
Option C is correct. Thionamides, including methimazole, block thyroid peroxidase (TPO)-mediated organification and iodotyrosine coupling, halting new thyroid hormone synthesis within hours of adequate dosing. However, the thyroid follicular colloid contains iodinated thyroglobulin representing approximately 2–3 months of preformed thyroid hormone storage. Methimazole does not block proteolysis of thyroglobulin or secretion of the preformed T4 and T3 already present in colloid. Clinical improvement requires that ongoing daily secretion depletes this reserve while new synthesis is arrested. The rate of depletion depends on the secretion rate — which is elevated in hyperthyroidism — and on colloid volume, typically requiring 2–4 weeks before circulating T4 and T3 fall substantially. This is why beta-blockade is initiated simultaneously to provide symptomatic relief during this lag.
Option A: Option A is incorrect; methimazole is not a prodrug requiring hepatic activation; it is active as administered and concentrates rapidly in thyroid tissue.
Option B: Option B is incorrect; TSIs do continue to stimulate the TSH receptor after methimazole initiation, but this merely maintains the signal driving colloid depletion — TPO inhibition is not overridden by TSI stimulation; the block is at the enzymatic synthesis step, which is downstream of receptor activation.
Option D: Option D is incorrect; methimazole achieves intrathyroidal concentrations rapidly; its pharmacokinetic profile (approximately 93% oral bioavailability, short plasma half-life with longer intrathyroidal concentration) does not produce a weeks-long delay to effective tissue levels.
Option E: Option E is incorrect; TSH normalization is a consequence of falling thyroid hormone levels, not a prerequisite; TSH remains suppressed until circulating T4 and T3 fall, but this sequence does not delay thyroid hormone clearance.
5. A 34-year-old woman started methimazole 6 weeks ago for Graves' disease. She calls the office reporting fever to 38.9°C (102°F) and a severe sore throat that began this morning. What is the most appropriate immediate instruction?
A) Reassure the patient that upper respiratory infections are common and she should continue methimazole; schedule an office visit in 3–5 days if symptoms persist
B) Advise the patient to take acetaminophen for fever, reduce her methimazole dose by half, and send a complete blood count (CBC) order for the next business day
C) Instruct the patient to stop methimazole and start the other thionamide (PTU) as a substitute while awaiting a CBC result
D) Order a throat culture by telemedicine and prescribe empirical amoxicillin, continuing methimazole pending culture results
E) Instruct the patient to stop methimazole immediately and go to the emergency department now for an urgent complete blood count to evaluate for agranulocytosis
ANSWER: E
Rationale:
Option E is correct. Agranulocytosis is a rare (0.1–0.5% incidence) but potentially fatal adverse effect of thionamide therapy, caused by immune-mediated destruction of granulocyte precursors. It typically presents as abrupt-onset fever and pharyngitis, most often within the first 90 days of treatment. Because agranulocytosis can develop between routine monitoring intervals and can deteriorate rapidly if the offending drug is continued, the management protocol is unambiguous: stop the drug immediately and obtain an urgent complete blood count (CBC) in the emergency department. Delayed evaluation — even by hours — risks ongoing immune-mediated destruction of remaining granulocyte precursors. Routine CBC monitoring in asymptomatic patients has not been shown to prevent mortality from agranulocytosis; the critical intervention is patient education at the time of prescription, followed by immediate cessation and urgent evaluation when symptoms occur. This education must be documented at every visit for patients on thionamides.
Option A: Option A is incorrect and dangerous; fever and pharyngitis in a thionamide-treated patient must be assumed to represent agranulocytosis until proven otherwise; reassurance and watchful waiting is contraindicated.
Option B: Option B is incorrect; dose reduction does not reverse agranulocytosis, and delaying CBC until the next business day allows potentially irreversible granulocyte depletion to continue.
Option C: Option C is incorrect; agranulocytosis is a class effect — a patient who develops agranulocytosis on methimazole must not be rechallenged with PTU, as cross-reactivity is well documented.
Option D: Option D is incorrect; empirical antibiotic initiation without first ruling out agranulocytosis, and continuing methimazole, is inappropriate; the sore throat may represent agranulocytosis-associated infection, not primary bacterial pharyngitis.
6. A 26-year-old woman with known Graves' disease, currently well-controlled on methimazole, presents at 7 weeks of gestation for her first prenatal visit. Her free T4 is normal and TSH remains mildly suppressed. Which of the following is the most appropriate adjustment to her antithyroid regimen?
A) Continue methimazole unchanged; its safety in early pregnancy is well established and switching risks thyroid hormone fluctuation
B) Switch to PTU immediately; methimazole is associated with embryopathy including aplasia cutis congenita and choanal atresia during organogenesis in weeks 6–10
C) Discontinue all antithyroid therapy; hyperthyroidism in early pregnancy is self-limited and thionamides carry greater fetal risk than the disease itself
D) Switch to radioactive iodine ablation; definitive therapy is preferred over long-term drug treatment during pregnancy
E) Add levothyroxine to block-and-replace; this strategy is safer than single-agent thionamide during the first trimester
ANSWER: B
Rationale:
Option B is correct. Methimazole carries a recognized teratogenic risk known as methimazole embryopathy, which includes aplasia cutis congenita (a scalp developmental defect), choanal atresia, esophageal atresia, and a broader methimazole embryopathy syndrome. These anomalies occur during organogenesis, specifically during weeks 6–10 of gestation when methimazole exposure is most harmful. PTU does not carry an equivalent teratogenic risk profile in the first trimester and is therefore the preferred thionamide for all pregnant patients during weeks 1–16. Switching at 7 weeks, while still within the organogenesis window, is urgent and appropriate.
Option A: Option A is incorrect; methimazole's safety in the first trimester is explicitly not well established — this PTU switch is a guideline-based recommendation from the American Thyroid Association (ATA) 2017 pregnancy guidelines and is not optional.
Option C: Option C is incorrect; untreated or undertreated hyperthyroidism in pregnancy carries significant maternal and fetal risks including preterm delivery, fetal growth restriction, and heart failure; drug discontinuation is not appropriate for a patient requiring antithyroid therapy for Graves' disease.
Option D: Option D is incorrect; radioactive iodine (RAI) is absolutely contraindicated throughout pregnancy because I-131 crosses the placenta and concentrates in the fetal thyroid after approximately 10–12 weeks of gestation, causing permanent fetal thyroid destruction.
Option E: Option E is incorrect; block-and-replace therapy is specifically contraindicated in pregnancy because the high-dose thionamide component crosses the placenta more readily than the replacement levothyroxine doses, risking fetal hypothyroidism and goiter.
7. A pregnant patient with Graves' disease was appropriately switched to PTU at 8 weeks of gestation. She is now at 16 weeks and her thyroid function tests are well controlled. What should be done with her antithyroid regimen at this point?
A) Continue PTU throughout pregnancy; it remains the safest thionamide for the full duration of gestation
B) Add propranolol to PTU to provide additional adrenergic control during the second trimester
C) Discontinue all antithyroid therapy since the immune tolerance of pregnancy typically resolves Graves' disease by the second trimester
D) Switch from PTU to methimazole; organogenesis is complete, eliminating the teratogenic concern for methimazole, and PTU carries a risk of fulminant hepatic necrosis with prolonged exposure
E) Switch from PTU to radioactive iodine since the fetal thyroid has not yet concentrated iodide at 16 weeks
ANSWER: D
Rationale:
Option D is correct. The PTU-to-methimazole switch at approximately 16 weeks of gestation is a guideline-mandated step in managing Graves' disease during pregnancy. PTU is the preferred first-trimester thionamide because methimazole embryopathy occurs during organogenesis at weeks 6–10. However, after organogenesis is complete (typically by week 16), the teratogenic rationale for using PTU over methimazole no longer applies. Continuing PTU through the second and third trimesters carries a significant risk of PTU-associated fulminant hepatic necrosis — an idiosyncratic hepatocellular injury pattern for which the FDA issued a black box warning. This risk is particularly relevant with prolonged exposure, as occurs in continued use through pregnancy. Switching to methimazole at 16 weeks eliminates this hepatotoxicity risk while accepting no increase in teratogenicity now that organogenesis is complete.
Option A: Option A is incorrect; PTU is NOT the safest thionamide for the full duration of pregnancy — it is the preferred agent only during the first trimester; its hepatotoxicity risk makes methimazole preferable for the remainder of pregnancy.
Option B: Option B is incorrect; adding propranolol to PTU is not the appropriate management step at 16 weeks; the indicated action is the thionamide switch, and beta-blockers are used adjunctively for symptoms, not as a routine second-trimester addition in well-controlled patients.
Option C: Option C is incorrect; while Graves' disease does often improve in the second and third trimesters due to immune tolerance, this is not predictable enough to justify discontinuing antithyroid therapy without close monitoring, and abrupt discontinuation in an active patient risks relapse.
Option E: Option E is incorrect; radioactive iodine is absolutely contraindicated throughout pregnancy; fetal thyroid iodide concentration begins around 10–12 weeks, and no dose of RAI is acceptable during gestation.
8. An endocrinologist is explaining antithyroid dosing strategies to a resident. Regarding the block-and-replace strategy — in which a high fixed dose of thionamide fully suppresses thyroid hormone synthesis while replacement levothyroxine maintains euthyroidism — which of the following is the most important contraindication to this approach?
A) Pregnancy, because the high-dose thionamide component crosses the placenta more readily than levothyroxine at replacement doses, risking fetal hypothyroidism and goiter
B) Patients with large goiters, because high-dose thionamide suppression causes paradoxical goiter enlargement through TSH stimulation
C) Patients over 60 years of age, because the combination of high-dose thionamide and levothyroxine increases the risk of atrial fibrillation
D) Patients with Graves' ophthalmopathy, because the combination increases the risk of orbital fibroblast activation
E) Renal impairment, because both methimazole and levothyroxine accumulate to toxic levels when glomerular filtration rate falls below 30 mL/min
ANSWER: A
Rationale:
Option A is correct. The block-and-replace strategy uses full-dose thionamide (typically methimazole 30–40 mg/day or equivalent PTU) combined with a fixed levothyroxine dose to maintain euthyroidism, eliminating the need for dose titration. This approach is specifically contraindicated in pregnancy because the high-dose thionamide crosses the placenta more readily than the levothyroxine dose required for replacement; fetal exposure to the thionamide exceeds the corrective effect of the levothyroxine (which crosses the placenta poorly and does not reliably protect the fetal thyroid axis), resulting in fetal and neonatal hypothyroidism, goiter, and neurodevelopmental risk. In pregnancy, the titrate-to-block strategy using the lowest effective thionamide dose is the required approach.
Option B: Option B is incorrect; high-dose thionamide suppression does cause TSH rise, and TSH stimulation can transiently worsen goiter size, but this is a recognized effect managed by dose titration, not an absolute contraindication; it is not the primary contraindication identified in guidelines.
Option C: Option C is incorrect; the combination of high-dose thionamide and levothyroxine is not specifically associated with increased atrial fibrillation risk in older patients; age is not a contraindication to block-and-replace in non-pregnant adults.
Option D: Option D is incorrect; Graves' ophthalmopathy severity correlates with overall thyroid autoimmune activity and TRAb levels, not specifically with the block-and-replace strategy; this approach does not independently worsen orbital disease.
Option E: Option E is incorrect; methimazole and levothyroxine do not accumulate to toxic levels with renal impairment; renal disease is not a contraindication to either drug or to the block-and-replace strategy.
9. A hyperthyroid patient requires urgent surgery. As part of pre-operative preparation, saturated solution of potassium iodide (SSKI) is added to reduce gland vascularity. Which of the following correctly describes the primary mechanism by which pharmacological doses of iodide acutely reduce thyroid hormone synthesis?
A) Pharmacological iodide competitively inhibits NIS (sodium-iodide symporter), reducing intracellular iodide availability for organification
B) Pharmacological iodide activates a negative feedback loop at the pituitary level, suppressing TSH secretion and thereby reducing follicular stimulation
C) Excess intracellular iodide transiently inhibits thyroid peroxidase (TPO)-mediated organification — the Wolff-Chaikoff effect — reducing new thyroid hormone synthesis within hours of administration
D) Pharmacological iodide cross-links thyroglobulin molecules in follicular colloid, physically blocking proteolytic release of preformed T4 and T3
E) Iodide at pharmacological doses chelates intracellular calcium, blocking the calcium-dependent exocytosis required for thyroid hormone secretion
ANSWER: C
Rationale:
Option C is correct. The Wolff-Chaikoff effect describes the phenomenon in which a large intracellular iodide load transiently inhibits thyroid peroxidase (TPO)-mediated organification — the oxidative incorporation of iodide into tyrosine residues on thyroglobulin. The precise molecular mechanism involves the generation of iodolipids that suppress TPO activity. This inhibitory effect develops within hours of pharmacological iodide administration (as Lugol's iodine or SSKI) and produces a rapid, temporary reduction in new thyroid hormone synthesis. In the pre-operative setting, iodide also has a separate beneficial effect of reducing gland vascularity and firmness over 7–14 days, making the thyroid technically more manageable during surgery. Importantly, the Wolff-Chaikoff effect is not durable — the thyroid escapes by downregulating NIS (sodium-iodide symporter), reducing intracellular iodide accumulation and restoring TPO activity within days to weeks; pharmacological iodide is therefore not appropriate as a long-term sole antithyroid treatment.
Option A: Option A is incorrect; pharmacological iodide is not an NIS inhibitor; it is transported by NIS into the follicular cell and then acts intracellularly. Competitive NIS inhibitors include perchlorate and thiocyanate.
Option B: Option B is incorrect; the pituitary negative feedback loop suppresses TSH in response to elevated thyroid hormone levels, not in direct response to iodide administration; iodide does not act at the pituitary level.
Option D: Option D is incorrect; pharmacological iodide does not cross-link thyroglobulin; glucocorticoids and iodide partially inhibit preformed hormone secretion by an incompletely understood mechanism, but it is not through thyroglobulin cross-linking.
Option E: Option E is incorrect; no clinically relevant mechanism of iodide action involves intracellular calcium chelation; thyroid hormone exocytosis is not the target of pharmacological iodide.
10. An intern is managing a patient in thyroid storm and asks about the correct sequencing of PTU and iodide (Lugol's solution). Which of the following correctly describes the required sequence and the pharmacological rationale for it?
A) Lugol's solution is given first to exploit the immediate Wolff-Chaikoff effect; PTU is then added 1 hour later once iodide organification is transiently suppressed
B) PTU and Lugol's solution are given simultaneously to ensure both mechanisms are engaged from the outset and prevent any delay in antithyroid effect
C) Lugol's solution is given first to reduce gland vascularity; PTU is delayed until after iodide has reduced thyroid blood flow and improved drug delivery to the gland
D) The sequence does not matter clinically since both PTU and Lugol's solution act on separate non-interacting pathways within the follicular cell
E) PTU must be given at least 1 hour before Lugol's solution; if iodide is administered first, excess iodide substrate reaches uninhibited TPO and may transiently increase thyroid hormone synthesis before the Wolff-Chaikoff effect is established
ANSWER: E
Rationale:
Option E is correct. The mandatory sequencing rule in thyroid storm is: thionamide loading first, followed by iodide no sooner than 1 hour later. The pharmacological rationale is straightforward: PTU (or methimazole) inhibits TPO, blocking organification of iodide. If Lugol's solution or SSKI is given before TPO is inhibited, the large iodide load provides abundant substrate to an uninhibited TPO enzyme; rather than producing the Wolff-Chaikoff effect immediately, a brief window exists during which new hormone synthesis may actually increase — a phenomenon sometimes described as a reverse Jod-Basedow effect. Once PTU has had at least 1 hour to inhibit TPO, subsequent iodide administration finds a blocked enzyme, eliminating the risk of paradoxical synthesis stimulation and allowing the Wolff-Chaikoff effect to operate on the background of already-inhibited organification. The correct thyroid storm sequence is: PTU 500–1000 mg PO/NG loading dose → wait 1 hour → Lugol's iodine or SSKI → propranolol IV/PO → hydrocortisone IV → supportive care.
Option A: Option A is incorrect; Lugol's solution must never precede thionamide in thyroid storm for the reason described above; administering iodide first risks a transient surge in thyroid hormone synthesis.
Option B: Option B is incorrect; simultaneous administration does not guarantee that PTU achieves sufficient TPO inhibition before the iodide load reaches follicular cells; the 1-hour wait is necessary to ensure meaningful enzyme inhibition before substrate is added.
Option C: Option C is incorrect; while iodide does reduce gland vascularity over 7–14 days, this is not a reason to administer iodide first in thyroid storm; the primary sequencing concern is enzymatic, not vascular.
Option D: Option D is incorrect; the pathways interact precisely at the TPO-iodide substrate interface, and sequence matters critically for the reasons described.
11. A 45-year-old man presents in thyroid storm. The team debates whether to use PTU or methimazole. Aside from their shared TPO inhibitory activity, which of the following correctly identifies the pharmacodynamic advantage of PTU over methimazole specifically in thyroid storm management?
A) PTU has higher oral bioavailability than methimazole and achieves faster peak thyroid tissue concentrations, providing quicker TPO inhibition
B) PTU inhibits type 1 deiodinase (D1), reducing peripheral conversion of T4 to the more potent T3, thereby producing a faster reduction in circulating T3 levels compared with methimazole
C) PTU has a longer plasma half-life than methimazole, allowing less frequent dosing during the intensive care phase of thyroid storm management
D) PTU inhibits thyroglobulin proteolysis, reducing the rate of preformed hormone release from follicular colloid during the acute crisis
E) PTU blocks beta-adrenergic receptors directly, providing dual antiadrenergic and antithyroid activity without the need for concurrent propranolol
ANSWER: B
Rationale:
Option B is correct. PTU's advantage in thyroid storm over methimazole lies specifically in its ability to inhibit type 1 deiodinase (D1), the enzyme responsible for the majority of extrathyroidal conversion of T4 (thyroxine) to T3 (triiodothyronine). T3 is approximately 3–4 times more potent than T4 at nuclear thyroid hormone receptors, and it is primarily the T3-mediated adrenergic hyperactivation — driving tachycardia, high-output hemodynamic compromise, and multi-organ stress — that produces the life-threatening manifestations of thyroid storm. PTU's D1 inhibition reduces peripheral T3 generation by approximately 40%, producing a faster fall in serum T3 than methimazole provides. This dual action on both synthesis (shared with methimazole) and peripheral conversion (unique to PTU) is the pharmacological rationale for PTU preference in storm.
Option A: Option A is incorrect; PTU actually has lower and more variable oral bioavailability (50–75%) compared with methimazole (approximately 93%), and slower absorption; bioavailability is an argument for methimazole, not PTU.
Option C: Option C is incorrect; PTU has a shorter plasma half-life (1–2 hours) than methimazole (4–6 hours), requiring three-times-daily dosing; this is a pharmacokinetic disadvantage of PTU, not an advantage.
Option D: Option D is incorrect; PTU does not inhibit thyroglobulin proteolysis; neither thionamide blocks the secretion of preformed hormone from colloid; that effect is partially achieved by iodide and glucocorticoids.
Option E: Option E is incorrect; PTU has no direct beta-adrenergic blocking activity; propranolol is required separately to provide adrenergic blockade and independently contributes D1 inhibition at high doses.
12. A 68-year-old woman is evaluated for hyperthyroidism. Thyroid scintigraphy shows patchy heterogeneous uptake with several hot nodules and suppressed uptake in the intervening parenchyma. TSH receptor antibodies (TRAb) are undetectable. Which of the following best explains why thionamide therapy will control her hyperthyroidism but cannot induce remission?
A) Thionamides are less effective at TPO inhibition in nodular thyroid tissue than in the diffuse follicular hyperplasia of Graves' disease
B) TRAb negativity indicates reduced follicular sensitivity to thionamides, so higher doses are required and drug resistance is common
C) Nodular thyroids have reduced vascularity and thionamide drug delivery is impaired compared with Graves' goiters
D) Toxic multinodular goiter (TMNG) results from somatic mutations in TSH receptor or Gsα subunit genes in follicular cells, producing constitutive cAMP activation independent of any immune process; thionamides suppress hormone synthesis but cannot reverse a somatic mutation or induce immunological remission
E) The heterogeneous uptake indicates that only a subset of nodules are actively secreting hormone; thionamides cannot selectively target hot nodules and cause collateral suppression of normal tissue
ANSWER: D
Rationale:
Option D is correct. Toxic multinodular goiter (TMNG) arises from somatic (acquired, non-germline) mutations in the TSH (thyroid-stimulating hormone) receptor gene or in the GNAS gene encoding the Gsα subunit of the stimulatory G protein. These mutations constitutively activate the cAMP signaling cascade within affected follicular clones, driving autonomous thyroid hormone synthesis and secretion that is independent of TSH or any immunoglobulin. Unlike Graves' disease, where the driving stimulus is an autoimmune TSI that can potentially be suppressed through immune modulation and spontaneous remission, TMNG has no autoimmune component — the mutations are permanent and cell-intrinsic. Thionamides are effective at inhibiting TPO and suppressing thyroid hormone output in TMNG, but withdrawal of the drug simply restores synthesis; there is no underlying immune process to resolve and no concept of immunological remission. Definitive therapy with RAI or surgery is therefore required.
Option A: Option A is incorrect; thionamides inhibit TPO by the same mechanism in nodular and non-nodular thyroid tissue; the molecular target is identical regardless of gland architecture.
Option B: Option B is incorrect; TRAb negativity simply confirms the absence of the Graves' autoimmune process; it does not imply thionamide resistance or reduced follicular sensitivity to TPO inhibition.
Option C: Option C is incorrect; thionamide drug delivery is not impaired by nodular gland architecture; oral bioavailability and thyroid tissue concentration are not significantly different between Graves' goiters and nodular goiters.
Option E: Option E is incorrect; thionamides inhibit TPO throughout the gland, including in hot nodules; the reason for lack of remission is not selective drug distribution but rather the permanent nature of the somatic mutations driving autonomous secretion.
13. A patient with Graves' disease developed confirmed agranulocytosis (absolute neutrophil count 180 cells/µL) while on methimazole 30 mg/day. Methimazole has been stopped and the patient has recovered with G-CSF (granulocyte-colony stimulating factor) support. The endocrine fellow asks whether PTU can now be used to control the hyperthyroidism while awaiting definitive therapy. Which response is most accurate?
A) PTU should not be used; thionamide-induced agranulocytosis is a class effect, and patients who develop agranulocytosis on one thionamide have significant cross-reactivity risk with the other
B) PTU is safe to use because its different chemical structure means it acts through a different immunological mechanism than methimazole-induced agranulocytosis
C) PTU can be used at a lower dose with CBC monitoring every 2 weeks, which reduces the risk of recurrent agranulocytosis to acceptable levels
D) PTU can be used temporarily since methimazole-induced agranulocytosis is dose-dependent and PTU-induced agranulocytosis only occurs with doses above 400 mg/day
E) PTU can be used because agranulocytosis from methimazole is caused by a drug-specific metabolite not shared with PTU
ANSWER: A
Rationale:
Option A is correct. Thionamide-induced agranulocytosis is classified as a class effect — a patient who develops this complication on one thionamide should not be rechallenged with the other. The immune-mediated mechanism responsible for granulocyte precursor destruction appears to involve sensitization to shared structural features of the thionamide drug class, not exclusively to a drug-specific metabolite. Cross-reactivity with recurrence of agranulocytosis upon switching to the alternative thionamide is well documented. Following thionamide-induced agranulocytosis, the patient should proceed directly to definitive therapy — either RAI (when medically stable) or surgery — using bridging pharmacological control with non-thionamide agents (high-dose iodide, glucocorticoids, beta-blockade, cholestyramine) as needed in the interval.
Option B: Option B is incorrect; while methimazole (imidazole structure) and PTU (thiouracil structure) have different chemical scaffolds, the agranulocytosis mechanism is not cleanly structure-specific; cross-reactivity has been reported and the clinical guideline is to avoid rechallenge with either thionamide.
Option C: Option C is incorrect; lower-dose PTU with CBC monitoring does not reliably prevent recurrence of agranulocytosis in a sensitized patient; because the reaction is idiosyncratic and can develop abruptly between monitoring intervals, this strategy does not provide an acceptable safety margin.
Option D: Option D is incorrect; thionamide-induced agranulocytosis is idiosyncratic, not dose-dependent in a predictable way; there is no safe lower-dose threshold that eliminates recurrence risk in a sensitized patient, and the 400 mg/day threshold for PTU hepatotoxicity is a separate concern.
Option E: Option E is incorrect; while drug-specific metabolite sensitization has been proposed as one mechanism, clinical evidence demonstrates cross-reactivity between the two thionamides, making the class-effect classification the operative clinical rule.
14. Propranolol is chosen over atenolol for a patient with severe symptomatic hyperthyroidism and a resting heart rate of 128 beats per minute. Beyond simple beta-adrenergic blockade, which additional pharmacodynamic property makes propranolol particularly useful in this setting?
A) Propranolol blocks alpha-1 adrenergic receptors in addition to beta receptors, providing more complete adrenergic suppression of thyroid hormone-driven vasoconstriction
B) Propranolol selectively inhibits type 2 deiodinase (D2) in the brain and pituitary, reducing central T3 levels and interrupting the hypothalamic-pituitary-thyroid (HPT) axis feedback loop
C) Propranolol inhibits type 1 deiodinase (D1) at doses of 80–160 mg/day, reducing peripheral conversion of T4 to the more potent T3 and lowering circulating T3 by approximately 10–20%
D) Propranolol directly inhibits TSH receptor signaling in follicular cells, reducing the TSI-driven stimulus for thyroid hormone synthesis
E) Propranolol inhibits thyroid hormone binding to plasma proteins, increasing the hepatic clearance of free T4 and accelerating hormone degradation
ANSWER: C
Rationale:
Option C is correct. Propranolol is a non-selective beta-adrenergic blocker that uniquely offers a second pharmacodynamic action at therapeutic doses used in hyperthyroidism: inhibition of type 1 deiodinase (D1), the peripheral enzyme responsible for the majority of T4-to-T3 conversion in the liver, kidney, and other extrathyroidal tissues. At doses of 80–160 mg/day — which are routinely used in severely symptomatic hyperthyroidism and thyroid storm — propranolol reduces circulating T3 by approximately 10–20% through D1 inhibition, adding a direct antithyroid hormonal effect to its adrenergic blockade. This dual mechanism is why propranolol is preferred over cardioselective agents such as atenolol and metoprolol, which lack D1 inhibitory activity, when maximal antithyroid benefit is needed alongside symptom control.
Option A: Option A is incorrect; propranolol is not an alpha-1 blocker; it is a non-selective beta (β1 and β2) blocker with no clinically significant alpha-adrenergic blocking activity.
Option B: Option B is incorrect; propranolol inhibits type 1 deiodinase (D1), not type 2 (D2); D2 is the major deiodinase in pituitary and neural tissues; propranolol does not selectively interrupt the HPT axis through D2 inhibition.
Option D: Option D is incorrect; propranolol has no direct action on TSH receptor signaling in thyroid follicular cells; it does not reduce TSI-driven cAMP activation; its antithyroid effects are entirely peripheral (D1 inhibition) and autonomic (beta-blockade).
Option E: Option E is incorrect; propranolol does not inhibit thyroid hormone binding to plasma proteins and does not accelerate hepatic T4 clearance through this mechanism; salicylates displace thyroid hormone from binding proteins, not propranolol.
15. A 42-year-old man with Graves' disease has mild proptosis and mild periorbital edema consistent with Graves' ophthalmopathy. He is otherwise a good candidate for radioactive iodine (RAI) ablation. What is the most appropriate management strategy regarding his ophthalmopathy and RAI?
A) RAI should be deferred indefinitely; any degree of Graves' ophthalmopathy is an absolute contraindication to RAI
B) RAI can proceed without modification; mild ophthalmopathy does not carry any risk of worsening with RAI compared with thionamide therapy
C) RAI should be replaced with surgery since glucocorticoids cannot be given concurrently with I-131 due to radiation interactions
D) RAI can be used only after complete resolution of ophthalmopathy, typically requiring 12–24 months of thionamide remission first
E) RAI can proceed with concurrent prophylactic oral glucocorticoids (e.g., prednisone approximately 0.4 mg/kg/day started on the day of RAI and tapered over 3 months), which reduces the risk of ophthalmopathy progression to near that seen with thionamide therapy
ANSWER: E
Rationale:
Option E is correct. RAI ablation is associated with new development or worsening of Graves' ophthalmopathy in approximately 15–20% of patients, compared with 3–5% in thionamide-treated patients. The mechanism involves RAI-induced release of thyroid antigens that trigger a surge in TRAb (TSH receptor antibody) titers and activation of TSH receptor-expressing orbital fibroblasts, promoting glycosaminoglycan deposition and orbital soft tissue expansion. However, mild ophthalmopathy is not an absolute contraindication to RAI — it is a modifiable risk factor. Prophylactic oral prednisone (approximately 0.4 mg/kg/day), started on the day of RAI administration and tapered over approximately 3 months, substantially reduces the risk of ophthalmopathy progression, with outcomes comparable to thionamide therapy in patients with mild pre-existing disease. This approach is endorsed by the EUGOGO (European Group on Graves' Orbitopathy) clinical practice guidelines. Risk is highest in current smokers, patients with high TRAb titers, and those with more severe baseline ophthalmopathy; smoking cessation counseling is an essential component of management.
Option A: Option A is incorrect; mild ophthalmopathy is not an absolute contraindication to RAI; it is a risk factor that can be managed with glucocorticoid prophylaxis. Active severe ophthalmopathy is a relative contraindication to RAI without glucocorticoid cover.
Option B: Option B is incorrect; untreated RAI does increase ophthalmopathy risk compared with thionamide therapy; mild pre-existing ophthalmopathy requires glucocorticoid prophylaxis, not simply proceeding without modification.
Option C: Option C is incorrect; there is no pharmacological interaction between oral glucocorticoids and I-131; concurrent administration is the guideline-recommended strategy.
Option D: Option D is incorrect; there is no evidence-based requirement for complete ophthalmopathy resolution or a 12–24 month thionamide remission period before RAI can be offered in patients with mild disease and appropriate glucocorticoid cover.
16. An endocrinology fellow asks about the hepatotoxicity profiles of the two thionamides. Which of the following correctly contrasts the hepatotoxicity patterns of methimazole and PTU?
A) Both methimazole and PTU cause identical cholestatic hepatotoxicity with elevated alkaline phosphatase and bilirubin; PTU carries a black box warning only because it is used at higher doses
B) Methimazole causes a typically mild cholestatic pattern with elevated alkaline phosphatase and bilirubin that is generally reversible on drug discontinuation; PTU causes an idiosyncratic fulminant hepatic necrosis with hepatocellular injury pattern that led to an FDA black box warning after cases of liver failure, transplantation, and death
C) PTU causes a mild transient elevation of liver enzymes in the first weeks of therapy that resolves with continued use; methimazole causes irreversible hepatic fibrosis with prolonged treatment
D) Methimazole causes hepatocellular injury predominantly in patients over age 60; PTU hepatotoxicity occurs only in pediatric patients, which is why the FDA black box warning applies exclusively to children
E) Both thionamides carry equivalent hepatotoxicity risk; the clinical differentiation is based on the presence of ANCA-associated vasculitis, which occurs with methimazole but not PTU
ANSWER: B
Rationale:
Option B is correct. The two thionamides have distinct and important differences in their hepatotoxicity profiles. Methimazole produces a cholestatic pattern of liver injury — characterized by elevated alkaline phosphatase and bilirubin — which is generally mild, self-limited, and reversible upon drug discontinuation. PTU, by contrast, causes an idiosyncratic hepatocellular injury pattern with frank hepatic necrosis; this is distinct from the cholestatic pattern and carries far greater severity. Following reports of liver failure, requirement for liver transplantation, and death — predominantly but not exclusively in pediatric patients — the FDA issued a black box warning for PTU hepatotoxicity in 2010. This divergent hepatotoxicity profile is a primary pharmacological rationale for preferring methimazole over PTU in most clinical situations outside the first trimester of pregnancy and thyroid storm.
Option A: Option A is incorrect; the two thionamides do not share identical cholestatic hepatotoxicity profiles; their injury patterns are mechanistically and clinically distinct.
Option C: Option C is incorrect; PTU does not cause transient elevations that resolve on continued therapy in the majority of cases; the concern is serious idiosyncratic hepatic necrosis, not a transient adaptive response. Methimazole does not cause hepatic fibrosis as a characteristic toxicity.
Option D: Option D is incorrect; while the black box warning arose from cases prominently involving pediatric patients, PTU hepatic necrosis occurs in adults as well; the black box warning is not exclusive to pediatric use, and methimazole hepatotoxicity does not have an age-specific pattern.
Option E: Option E is incorrect; the hepatotoxicity risk profiles are not equivalent; furthermore, ANCA (antineutrophil cytoplasmic antibody)-associated vasculitis occurs more commonly with PTU (reported prevalence up to 4% in long-term users), not with methimazole — making this option incorrect in both assertions.
17. A patient in thyroid storm develops a fever of 39.8°C (103.6°F). A nurse asks whether aspirin can be given for fever management. Which of the following correctly explains why salicylates are specifically avoided in thyroid storm?
A) Salicylates inhibit hepatic glucuronidation of T4, slowing thyroid hormone clearance and prolonging the thyrotoxic state
B) Salicylates activate beta-adrenergic receptors through prostaglandin E2 inhibition, worsening the adrenergic hyperactivation of thyroid storm
C) Salicylates inhibit type 1 deiodinase (D1), paradoxically increasing T4 levels by blocking peripheral conversion and worsening thyroid storm
D) Salicylates displace T4 and T3 from plasma binding proteins (thyroxine-binding globulin, transthyretin, and albumin), acutely raising free hormone concentrations at a time when end-organ stress is already maximal
E) Salicylates competitively inhibit cellular thyroid hormone uptake transporters (MCT8), reducing tissue T3 clearance and prolonging receptor-level hormonal activity
ANSWER: D
Rationale:
Option D is correct. Salicylates — including aspirin and other salicylate-class compounds — compete with thyroid hormones for binding sites on plasma proteins, specifically thyroxine-binding globulin (TBG), transthyretin (also called thyroxine-binding prealbumin), and albumin. Under normal circumstances the vast majority of circulating T4 (approximately 99.97%) and T3 (approximately 99.7%) is protein-bound; only the small free fraction is biologically active. When salicylates displace thyroid hormone from these binding sites, the free hormone concentration rises acutely. In thyroid storm — where end-organ adrenergic stress, hemodynamic compromise, and multi-organ dysfunction are already at critical levels — even a transient increase in free T3 and T4 can worsen the physiological decompensation at a moment when the patient's reserves are fully exhausted. Acetaminophen does not displace thyroid hormone from binding proteins and is the exclusively appropriate analgesic/antipyretic in thyroid storm.
Option A: Option A is incorrect; salicylates do not significantly inhibit hepatic glucuronidation of T4 to a clinically relevant degree; thyroid hormone clearance is not the primary concern.
Option B: Option B is incorrect; salicylates inhibit prostaglandin synthesis via COX (cyclooxygenase) inhibition, but this does not activate beta-adrenergic receptors; the adrenergic mechanism of salicylate toxicity in thyroid storm is not a recognized concern.
Option C: Option C is incorrect; salicylates do not inhibit type 1 deiodinase; D1 inhibition is the mechanism of PTU and propranolol.
Option E: Option E is incorrect; MCT8 (monocarboxylate transporter 8) inhibition by salicylates is not a recognized pharmacological mechanism at therapeutic doses; the protein-binding displacement effect is the established concern.
18. A surgeon plans total thyroidectomy for a patient with Graves' disease. In addition to achieving biochemical euthyroidism with methimazole, Lugol's solution (5–10 drops three times daily for 7–10 days) is added immediately before surgery. Which of the following best describes the pharmacological purpose of this pre-operative iodide administration?
A) Pre-operative iodide reduces thyroid gland vascularity and firmness over 7–14 days by a mechanism distinct from its effect on hormone synthesis, making the gland less vascular and technically more manageable at surgery, while also transiently reducing hormone synthesis via the Wolff-Chaikoff effect
B) Pre-operative iodide is given to load thyroid follicular cells with stable iodide, competitively inhibiting post-operative radioactive iodine uptake if RAI is subsequently needed for residual disease
C) Pre-operative iodide permanently downregulates NIS (sodium-iodide symporter) expression, providing lasting protection against post-operative thyrotoxicosis from residual thyroid tissue
D) Pre-operative iodide is given to saturate thyroid binding proteins and prevent intraoperative release of free T4 into the circulation during surgical manipulation of the gland
E) Pre-operative iodide inhibits thyrotropin receptor antibody (TRAb) production by B cells, reducing the autoimmune stimulus and decreasing the risk of post-operative Graves' ophthalmopathy flare
ANSWER: A
Rationale:
Option A is correct. Pharmacological iodide administered in the days immediately before thyroidectomy serves two complementary purposes. First, via the Wolff-Chaikoff effect, excess intracellular iodide transiently inhibits TPO-mediated organification, reducing ongoing thyroid hormone synthesis during the pre-operative period. Second — and specifically important for surgical planning — pharmacological iodide reduces thyroid gland vascularity and firmness over 7–14 days through a mechanism that is incompletely understood but is distinct from its effect on hormone synthesis. This vascular effect converts the hypervascular, friable Graves' goiter into a firmer, less bloody surgical specimen, reducing intraoperative blood loss and facilitating a technically safer total thyroidectomy. Both effects together — not just hormone synthesis inhibition — are the rationale for the 7–10 day pre-operative iodide course. Lugol's iodine (approximately 8 mg iodide per drop) is the standard preparation; SSKI (saturated solution of potassium iodide, approximately 38 mg per drop) is an alternative.
Option B: Option B is incorrect; loading with stable iodide does transiently reduce RAI uptake efficiency, but this is actually a potential concern (methimazole must be stopped and iodide avoided before RAI), not a purpose of pre-operative iodide in the surgical pathway.
Option C: Option C is incorrect; iodide does cause NIS downregulation as part of the escape from the Wolff-Chaikoff effect, but this is a temporary adaptation, not permanent; it does not provide lasting protection against post-operative thyrotoxicosis.
Option D: Option D is incorrect; thyroid hormone binding to plasma proteins is not affected by pharmacological iodide administration; intraoperative hormone release into the circulation is not a clinically recognized concern that iodide is designed to prevent.
Option E: Option E is incorrect; pharmacological iodide does not inhibit TRAb production by B cells; the immune process driving Graves' disease is not directly suppressed by iodide.
19. In a patient with severe thyroid storm, the team adds cholestyramine (a bile acid sequestrant) 4 g four times daily as an adjunct to the standard multi-drug protocol. Which of the following correctly explains the mechanism by which cholestyramine helps lower circulating thyroid hormone levels?
A) Cholestyramine inhibits NIS (sodium-iodide symporter)-mediated iodide uptake in thyroid follicular cells, reducing the substrate available for thyroid hormone synthesis
B) Cholestyramine inhibits hepatic deiodinase enzymes, slowing the conversion of T4 to T3 and allowing unmetabolized T4 to be excreted renally
C) Cholestyramine binds thyroid hormone in the intestinal lumen, interrupting enterohepatic recirculation of T4 and T3 and increasing fecal hormone elimination, thereby reducing the effective circulating pool
D) Cholestyramine competitively displaces thyroid hormone from thyroxine-binding globulin (TBG), increasing the free fraction available for hepatic glucuronidation and accelerating overall clearance
E) Cholestyramine inhibits the hepatic organic anion transporting polypeptide (OATP) transporters responsible for thyroid hormone uptake, reducing intrahepatic T4 reactivation
ANSWER: C
Rationale:
Option C is correct. Cholestyramine is a non-absorbable anion exchange resin that binds organic anions — including bile acids and, importantly, thyroid hormones — within the intestinal lumen. Thyroid hormone undergoes significant enterohepatic recirculation: T4 and T3 are conjugated in the liver (glucuronidation and sulfation), excreted into bile, and then undergo intestinal deconjugation and reabsorption. By binding thyroid hormone in the intestinal lumen, cholestyramine prevents this reabsorption step, directing hormone conjugates toward fecal elimination. The result is a net reduction in the circulating thyroid hormone pool. At 4 g four times daily, cholestyramine can accelerate the decline of T4 and T3 levels and is used as an adjunct in thyroid storm or when rapid pharmacological control is needed. It is also useful when iodide-based approaches are contraindicated or as adjunctive therapy in severe cases not controlled by standard agents.
Option A: Option A is incorrect; cholestyramine is a gastrointestinal resin with no NIS-inhibitory activity in thyroid tissue; it does not affect iodide uptake into follicular cells.
Option B: Option B is incorrect; cholestyramine does not inhibit hepatic deiodinase enzymes; it acts entirely within the intestinal lumen and has no systemic enzymatic effects on thyroid hormone metabolism.
Option D: Option D is incorrect; cholestyramine does not interact with thyroxine-binding globulin (TBG) in plasma; it is non-absorbable and confined to the gastrointestinal lumen where it binds free hormone, not plasma protein-bound fractions.
Option E: Option E is incorrect; cholestyramine does not inhibit OATP (organic anion transporting polypeptide) hepatic transporters; its mechanism is entirely intraluminal binding of unabsorbed or enterohepatic-cycle hormone.
20. Hydrocortisone 100 mg IV every 8 hours is added to the thyroid storm protocol for a critically ill patient. Which of the following most completely explains the pharmacological rationale for glucocorticoid use in thyroid storm?
A) Glucocorticoids reduce the inflammatory response triggered by elevated TSI levels, lowering TRAb titers acutely and reducing the autoimmune drive on thyroid hormone secretion
B) Glucocorticoids stabilize the blood-brain barrier, preventing the CNS manifestations of thyroid storm including agitation, psychosis, and coma
C) Glucocorticoids inhibit NIS (sodium-iodide symporter) expression, reducing iodide uptake and serving as an alternative to pharmacological iodide preparations
D) Glucocorticoids block TSH receptor signaling by occupying a shared intracellular cAMP response element, reducing the biological effect of circulating TSIs
E) Glucocorticoids serve three mechanisms in thyroid storm: they inhibit thyroid hormone secretion by reducing glandular release of preformed hormone, inhibit peripheral type 1 deiodinase (D1) reducing T3 generation, and cover the possibility of relative adrenal insufficiency in a patient under extreme physiological stress
ANSWER: E
Rationale:
Option E is correct. Glucocorticoids — given as hydrocortisone 100 mg IV every 8 hours or dexamethasone 2 mg IV every 6 hours — are mandatory components of thyroid storm management for three distinct reasons that together justify their use. First, they partially inhibit thyroid hormone secretion by reducing the glandular release of preformed T4 and T3 from thyroglobulin colloid. Second, they inhibit peripheral type 1 deiodinase (D1) activity, reducing the conversion of T4 to the more potent T3 and thereby lowering circulating T3 levels — the same D1 inhibitory mechanism exploited by PTU and high-dose propranolol. Third, severe physiological stress — including the multi-organ decompensation of thyroid storm — can unmask relative adrenal insufficiency; glucocorticoids provide essential adrenal axis coverage in this context. No single mechanism alone fully explains the mandate for glucocorticoids in thyroid storm; it is this three-mechanism rationale that makes them a required, not optional, component of the protocol.
Option A: Option A is incorrect; glucocorticoids do not acutely reduce TRAb titers in thyroid storm; while prolonged immunosuppression can affect autoimmune processes, acute glucocorticoid dosing in storm is not driven by TRAb suppression.
Option B: Option B is incorrect; blood-brain barrier stabilization is not the primary or even secondary rationale for glucocorticoids in thyroid storm; CNS manifestations are managed through the overall reduction of thyroid hormone excess.
Option C: Option C is incorrect; glucocorticoids do not inhibit NIS expression in the acute setting; this is not a recognized mechanism of glucocorticoid action relevant to thyroid storm management.
Option D: Option D is incorrect; glucocorticoids do not block TSH receptor signaling through a shared cAMP response element; their antithyroid effects operate at the secretory and peripheral metabolic levels, not at the receptor-signaling level.
21. A 35-year-old woman with Graves' disease has completed 18 months of methimazole therapy. She is currently euthyroid and feels well. Her TRAb (TSH receptor antibody) titer remains elevated at 3.8 times the upper reference limit. She asks whether she can simply stop methimazole and monitor. Which of the following is the most appropriate clinical response?
A) Inform her that a persistently elevated TRAb is expected at 18 months and does not predict relapse; methimazole can be discontinued and monitoring with annual TSH is sufficient
B) Explain that persistently elevated TRAb at the completion of a standard treatment course is a strong predictor of hyperthyroid relapse after thionamide discontinuation; relapse rates approach 60–70% within one year; definitive therapy with RAI or thyroidectomy should be recommended
C) Advise that she should continue methimazole for an additional 24 months since a second treatment course consistently achieves remission in patients with initially elevated TRAb
D) Recommend adding levothyroxine to her current methimazole in a block-and-replace strategy to suppress TRAb titers to normal before attempting drug discontinuation
E) Advise that TRAb titers are not clinically useful for predicting relapse after thionamide therapy and that the decision to stop methimazole should be based on thyroid ultrasound volume alone
ANSWER: B
Rationale:
Option B is correct. TRAb (TSH receptor antibodies) measured at the completion of a standard thionamide treatment course are the most clinically useful predictor of relapse in Graves' disease. Patients with TRAb titers that remain elevated — particularly at levels well above the upper reference limit — at 12–18 months of therapy have high relapse rates, with published data showing 60–70% recurrence within one year of methimazole discontinuation in this group. This stands in contrast to patients in whom TRAb normalize during treatment, who have substantially better remission rates (40–60% overall across the Graves' population). When TRAb remain markedly elevated at the end of a standard treatment course, the evidence does not support simply stopping the drug; counseling toward definitive therapy — radioactive iodine (RAI) or thyroidectomy — is the appropriate clinical response.
Option A: Option A is incorrect; persistently elevated TRAb at treatment completion is not a normal finding to be dismissed; it is a validated predictor of relapse risk and should inform therapeutic decision-making.
Option C: Option C is incorrect; a second course of thionamide therapy in a patient who has not normalized TRAb after 18 months rarely achieves durable remission; the remission rate for a second course is substantially lower than for the first, and definitive therapy should be recommended rather than retreatment.
Option D: Option D is incorrect; block-and-replace strategy does not suppress TRAb titers more effectively than titrate-to-block therapy; the immunological driver of TRAb production is not directly reduced by the dosing strategy, and block-and-replace does not serve as a bridge to thionamide-free remission in TRAb-positive patients.
Option E: Option E is incorrect; TRAb titers are clinically validated predictors of relapse and are specifically recommended in ATA guidelines for monitoring Graves' disease patients considering thionamide discontinuation; thyroid volume alone is insufficient for this prediction.
22. A pharmacist questions why methimazole is commonly dosed once daily despite having a plasma half-life of only 4–6 hours. A physician explains that once-daily dosing is pharmacologically justified. Which of the following correctly explains this apparent discrepancy?
A) Methimazole undergoes zero-order pharmacokinetics at therapeutic doses, meaning plasma levels remain constant once steady state is achieved, making plasma half-life clinically irrelevant to dosing frequency
B) Methimazole is a prodrug with a long-acting active metabolite (carbimazole) that sustains TPO inhibition independent of the parent drug's plasma half-life
C) Methimazole inhibits TPO irreversibly; once enzyme inhibition is established, new TPO synthesis is required to restore activity, which takes 24 hours regardless of drug plasma levels
D) Methimazole concentrates in thyroid tissue, where its intrathyroidal half-life is substantially longer than the plasma half-life; sustained intrathyroidal concentrations maintain TPO inhibition throughout a once-daily dosing interval despite rapid plasma clearance
E) Methimazole's TPO inhibitory effect requires only 2–3 hours of drug-enzyme contact to produce irreversible covalent modification; after this brief window, ongoing plasma drug levels are not needed to sustain the inhibitory effect
ANSWER: D
Rationale:
Option D is correct. The apparent pharmacokinetic paradox of once-daily methimazole dosing despite a short plasma half-life of 4–6 hours is explained by the drug's preferential concentration in thyroid tissue. After oral administration, methimazole achieves intrathyroidal concentrations that are substantially higher than plasma levels, and the intrathyroidal half-life is considerably longer than the plasma half-life. This tissue accumulation and prolonged retention within the thyroid gland sustains TPO inhibition throughout the 24-hour dosing interval even after plasma levels have declined to low values. Clinical studies have confirmed equivalent thyroid function control with once-daily versus divided dosing of methimazole at standard doses (10–40 mg/day), validating this pharmacokinetic rationale. Once-daily dosing improves patient adherence without sacrificing efficacy — a significant practical advantage over PTU, which requires three-times-daily dosing due to its shorter and less tissue-retentive pharmacokinetic profile.
Option A: Option A is incorrect; methimazole does not exhibit zero-order pharmacokinetics at therapeutic doses; it follows standard first-order elimination, and plasma half-life is not irrelevant.
Option B: Option B is incorrect; carbimazole is the prodrug that is converted to methimazole in vivo; methimazole itself is the active form, not carbimazole; this option inverts the prodrug relationship.
Option C: Option C is incorrect; methimazole inhibits TPO through competitive or pseudo-irreversible binding within the TPO active site involving the iodide organification cycle, but this is not a simple 24-hour enzyme regeneration cycle; the mechanism of once-daily efficacy is intrathyroidal concentration, not the kinetics of TPO resynthesis.
Option E: Option E is incorrect; methimazole does not produce a brief 2–3 hour covalent modification that independently sustains inhibition; TPO activity returns as drug levels fall unless maintained by intrathyroidal concentrations; persistent tissue drug levels are required throughout the dosing interval.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.